Lastly, a correlation between reduced TGF-β1 plasma levels, depression severity, and treatment resistance in MDD has been proved (Sutcigil et al., 2007; Caraci et al., 2018a). This evidence concerns the gene TGFB1 and depressive symptom measurement.